SGEN - Seattle Genetics, Inc.
| Previous Close | 55.37 |
| Open | 55.45 |
| Bid | 55.00 x 800 |
| Ask | 59.00 x 1200 |
| Day's Range | 55.01 - 56.01 |
| 52 Week Range | 45.31 - 66.35 |
| Volume | 331,257 |
| Avg. Volume | 904,668 |
| Market Cap | 8.827B |
| Beta | 1.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.88 |
| Earnings Date | Jul 25, 2018 - Jul 30, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 65.50 |
- Market Realist•8 days ago
Why Wall Street Analysts Are Mostly Positive on CRISPR
In December 2017, CRISPR Therapeutics (CRSP) entered a collaboration with Vertex Pharmaceuticals (VRTX) for the co-development and co-commercialization of CTX001. CRISPR Therapeutics submitted a CTA (clinical trial application) for CTX001 for the initiation of phase 1/2 trial for the evaluation of the safety and efficacy in the treatment of beta-thalassemia in Europe. CRISPR Therapeutics plans to submit an Investigational New Drug application to the FDA for the approval of an initiation of phase 1/2 clinical trial in the US for the treatment of sickle cell disease in the second half of 2018.
- Business Wire•9 days ago
Seattle Genetics Appoints Roger D. Dansey, M.D., Chief Medical Officer
Seattle Genetics, Inc. (SGEN) today announced the appointment of Roger D. Dansey, M.D., as Chief Medical Officer. Dr. Dansey brings extensive experience in cancer drug development, most recently from Merck Inc. where he was Therapeutic Area Head for Late Stage Oncology, responsible for the ongoing registration efforts for KEYTRUDA® (pembrolizumab) across multiple tumor types. “Roger’s appointment reflects the growing importance of late-stage clinical drug development at Seattle Genetics as we transition to a global, multi-product oncology company,” said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics.
- Business Wire•9 days ago
Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting
Seattle Genetics, Inc. today announced that multiple abstracts from its robust clinical development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, from June 1-5, 2018.
- Investopedia•12 days ago
4 Biotech Stocks Set to Rise By 14% or More
Biotech stocks are breaking out, with the SPDR S&P Biotech ETF ( XBI) gearing up for what could be a significant rise higher. Since that time the group has turned higher, and now technical analysis suggests more gains may lie ahead for the sector.
- GlobeNewswire•17 days ago
Factors of Influence in 2018, Key Indicators and Opportunity within Patterson Companies, Zayo Group, Six Flags Entertainment Corporation New, Leucadia National, Seattle Genetics, and RPC — New Research Emphasizes Economic Growth
NEW YORK, May 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Patterson ...
- ACCESSWIRE•22 days ago
Blog Exposure - Cellectar Receives Rare Pediatric Disease Designation from FDA
LONDON, UK / ACCESSWIRE / May 4, 2018 / If you want access to our free research report on Cellectar Biosciences, Inc. (NASDAQ: CLRB) ("Cellectar") all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CLRB as the Company's latest news hit the wire. On May 02, 2018, the Company announced that the US Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation (RPDD) to its lead phospholipid drug conjugate, CLR 131, for the treatment of neuroblastoma. Active-Investors.com is currently working on the research report for Seattle Genetics, Inc. (NASDAQ: SGEN), which also belongs to the Healthcare sector as the Company Cellectar Biosciences.
- American City Business Journals•23 days ago
The Bothell economy: City looks to Lake Union area as model to build up biotech hub
Bothell's future as a thriving biotech hub hinges on its ability to compete with Seattle's Lake Union area. That's prompting changes that aim to make Bothell's business district a great place to work and play.
- Motley Fool•24 days ago
Seattle Genetics Accelerates Revenue Growth, Earnings Not So Much
An expanded approval has doctors prescribing the biotech's blood cancer drug, Adcertis, to more patients.
- Business Wire•24 days ago
Seattle Genetics to Present at the Bank of America Merrill Lynch Health Care Conference 2018
Seattle Genetics, Inc. announced today that management will present at the Bank of America Merrill Lynch Health Care Conference 2018 on Tuesday, May 15, 2018 at 5:00 p.m.
- Thomson Reuters StreetEvents•28 days ago
Edited Transcript of SGEN earnings conference call or presentation 26-Apr-18 8:30pm GMT
Q1 2018 Seattle Genetics Inc Earnings Call
- Motley Fool•29 days ago
Why Seattle Genetics Jumped Higher Today
An expanded approval of blood cancer drug Adcetris is paying off.
- Zacks•29 days ago
Seattle Genetics (SGEN) Q1 Earnings Lag Estimates, Sales Top
Seattle Genetics (SGEN) first-quarter earnings miss estimates while sales beat the same.
- American City Business Journals•29 days ago
Seattle Genetics searches for 10th building in effort to keep up with growth
The company is the state's largest biotech, and has been growing quickly. Now, it's on the hunt for another building. Seattle Genetics is looking for a building that includes office and lab space. The company will likely remodel the new building.
- Associated Press•last month
Seattle Genetics: 1Q Earnings Snapshot
On a per-share basis, the Bothell, Washington-based company said it had a loss of 73 cents. Losses, adjusted for non-recurring costs, were 61 cents per share. The results did not meet Wall Street expectations. ...
- Business Wire•last month
Seattle Genetics Reports First Quarter 2018 Financial Results
Seattle Genetics, Inc. today reported financial results for the first quarter ended March 31, 2018. The company also highlighted ADCETRIS commercialization and clinical development accomplishments, and progress with its late-stage clinical programs and pipeline of targeted therapies for cancer.
- American City Business Journals•last month
Seattle Genetics searches for its 10th building to keep up with growth
The Seattle-area’s largest biotech already has a footprint of about 500,000 square feet, which includes seven office buildings in Bothell, a manufacturing facility in North Creek and a Seattle office.
- Business Wire•last month
Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American Association for Cancer Research (AACR) Annual Meeting
Seattle Genetics, Inc. today announced data highlights from nine presentations showcasing the company’s innovative, proprietary antibody-drug conjugate platform technologies as well as its emerging immuno-oncology pipeline.
Markit•2 months agoSee what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGEN
- Business Wire•2 months ago
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 26, 2018
Seattle Genetics, Inc. announced today that it will report its first quarter financial results on Thursday, April 26, 2018 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
- Zacks•2 months ago
Biotech Stock Roundup: PTGX Down, VRNA Up, AMGN's Repatha Gets Positive Opinion
The biotech sector was in focus last week with Protagonist's stock plunging on news of discontinuation of a phase IIb study and Verona Pharma stock surging on positive top-line data from COPD study among others.
- Market Realist•2 months ago
Key Updates on Akcea Therapeutics’ Volanesorsen
How Ionis Pharmaceuticals Is Positioned in 2018
- American City Business Journals•2 months ago
Seattle Genetics wins FDA approval for cancer drug that could push U.S. sales past $1 billion
“This marks the first time in four decades and 10 different attempts to replace one of the most toxic drugs ... for late-stage classical Hodgkin while increasing long-term survival,” founder and CEO Clay Siegall said.
- Market Realist•2 months ago
A Look at Ionis’s Key Revenue Drivers in 4Q17
How Ionis Pharmaceuticals Is Positioned in 2018
- PR Newswire•2 months ago
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
TOKYO and BOTHELL, Wash., March 26, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Seattle Genetics, Inc. (SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC), for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors (CPI). Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition.
- Business Wire•2 months ago
Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Seattle Genetics, Inc. and Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate , for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors .
